From: Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program
Mean ARR
Participants (n = 190)
Non-participants (n = 137)
During12 months before baseline
1.2
From baseline to month 12 of study
0.5
Relative reduction of relapse rate
58 %